BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. (BLFS) Healthcare & Pipeline Overview

BioLife Solutions is a key player in the cell and gene therapy industry, providing biopreservation media, automated thawing equipment, and cryogenic storage solutions. With a focus on mitigating cell damage during preservation, they serve a critical need in the rapidly growing biologics market, primarily in the United States, Canada, and Europe.

What Is the Investment Thesis for BLFS?

BioLife Solutions presents a notable research candidate within the rapidly expanding cell and gene therapy market. The company's proprietary biopreservation media and automated thawing solutions address a critical need in ensuring the viability and efficacy of cell-based therapies. With a gross margin of 64.0%, BioLife Solutions demonstrates strong pricing power and efficient operations. Key growth catalysts include the increasing adoption of cell and gene therapies, expansion into new geographic markets, and strategic acquisitions to broaden their product portfolio. However, potential risks include competition from alternative preservation methods, regulatory hurdles, and the inherent volatility associated with the biotechnology sector. The company's beta of 2.00 indicates a higher-than-average sensitivity to market fluctuations. Investors should closely monitor revenue growth, customer retention rates, and the company's ability to maintain its competitive edge in this dynamic market.

Based on FMP financials and quantitative analysis

BLFS Key Highlights

• Market Cap of $1.36B reflects investor confidence in BioLife Solutions' growth potential within the cell and gene therapy market.
• Gross Margin of 64.0% indicates strong pricing power and efficient cost management in the bioproduction tools and services sector.
• Negative Profit Margin of -10.5% suggests ongoing investments in R&D and expansion efforts, which may impact near-term profitability but drive long-term growth.
• Beta of 2.00 indicates higher volatility compared to the overall market, reflecting the growth-oriented nature of the company and its industry.
• Focus on cell and gene therapy bioproduction tools and services positions BioLife Solutions to capitalize on the increasing demand for these therapies.

Who Are BLFS's Competitors?

BLFS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BLFS's Key Strengths?

• Proprietary biopreservation media formulations.
• Automated ThawSTAR thawing technology.
• Strong relationships with cell and gene therapy companies.
• Comprehensive product portfolio.

What Are BLFS's Weaknesses?

• Negative profit margin.
• High beta indicating market volatility.
• Reliance on the growth of the cell and gene therapy market.
• Limited geographic diversification.

What Could Drive BLFS Stock Higher?

• Increasing adoption of cell and gene therapies driving demand for biopreservation solutions.
• Expansion of BioLife Solutions' product portfolio through strategic acquisitions.
• Potential regulatory approvals for new cell and gene therapies utilizing BioLife Solutions' products.
• Launch of new biopreservation media formulations with improved cell viability.
• Growing demand for biological and pharmaceutical storage services.

What Are the Key Risks for BLFS?

• Negative return on equity (-2.9%) — the business is not currently generating profit on shareholder capital.
• Competition from alternative preservation methods and cryogenic storage solutions.
• Regulatory hurdles for cell and gene therapies impacting market growth.
• Economic downturn reducing research and development spending.
• Reliance on the growth of the cell and gene therapy market.
• Patent expirations on key products impacting revenue.

What Are the Growth Opportunities for BLFS?

• Expansion into Emerging Markets: BioLife Solutions has the opportunity to expand its presence in emerging markets, such as Asia-Pacific and Latin America, where the demand for cell and gene therapies is growing rapidly. By establishing strategic partnerships and distribution networks in these regions, the company can tap into new customer segments and drive revenue growth. The global cell therapy market is projected to reach $48.61 billion by 2029, presenting a significant opportunity for BioLife Solutions to capitalize on this expansion.
• Strategic Acquisitions: BioLife Solutions can pursue strategic acquisitions to broaden its product portfolio and expand its capabilities in related areas, such as cell culture media, cell processing equipment, and quality control testing. By acquiring complementary businesses, the company can offer a more comprehensive suite of solutions to its customers and strengthen its competitive position. The market for cell culture media is expected to reach $7.7 billion by 2027, offering potential acquisition targets for BioLife Solutions.
• Development of New Biopreservation Media: BioLife Solutions can invest in the development of new biopreservation media formulations that offer improved cell viability and stability for a wider range of cell types and therapeutic applications. By continuously innovating its media products, the company can maintain its competitive edge and attract new customers. The global biopreservation market is projected to reach $5.5 billion by 2028, driven by the increasing demand for high-quality preservation solutions.
• Enhancement of Thawing Technology: BioLife Solutions can further enhance its ThawSTAR thawing technology to improve the speed, consistency, and automation of the thawing process. By developing new features and capabilities, such as integrated data logging and remote monitoring, the company can differentiate its thawing products and attract customers seeking advanced thawing solutions. The market for automated thawing systems is expected to grow significantly in the coming years, driven by the increasing adoption of cell and gene therapies.
• Expansion of Storage Services: BioLife Solutions can expand its biological and pharmaceutical storage services to meet the growing demand for secure and reliable storage of temperature-sensitive materials. By offering a range of storage options, including cryogenic storage and ultra-low temperature freezers, the company can cater to the diverse needs of its customers. The global market for biostorage is projected to reach $8.5 billion by 2027, presenting a significant opportunity for BioLife Solutions to expand its storage services.

What Opportunities Does BLFS Have?

• Expansion into emerging markets.
• Strategic acquisitions of complementary businesses.
• Development of new biopreservation media formulations.
• Enhancement of ThawSTAR thawing technology.

What Threats Does BLFS Face?

• Competition from alternative preservation methods.
• Regulatory hurdles for cell and gene therapies.
• Economic downturn impacting research and development spending.
• Patent expirations on key products.

What Are BLFS's Competitive Advantages?

• Proprietary biopreservation media formulations (HypoThermosol FRS and CryoStor).
• Automated ThawSTAR thawing technology.
• Established relationships with leading cell and gene therapy companies.
• Comprehensive product portfolio spanning biopreservation, thawing, and storage solutions.

What Does BLFS Do?

BioLife Solutions, Inc., founded in 1987 and headquartered in Bothell, Washington, is a leading developer, manufacturer, and supplier of bioproduction tools and services specifically tailored for the cell and gene therapy industry. The company's inception was driven by the need for improved methods of preserving biological materials used in research and clinical applications. Over the years, BioLife Solutions has evolved from a niche provider of biopreservation media to a comprehensive solutions provider, offering a range of products and services that support the entire bioproduction workflow. Their core product offerings include proprietary biopreservation media such as HypoThermosol FRS and CryoStor, which are formulated to minimize cell damage and death during the preservation process. Additionally, BioLife Solutions offers the ThawSTAR line of automated thawing products, designed to precisely control the thawing process of biologic materials in vials and cryobags. The company also provides evo shipping containers, which are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals, as well as liquid nitrogen laboratory freezers, cryogenic equipment, and biological and pharmaceutical storage services. BioLife Solutions markets and sells its products directly and through a network of third-party distributors, serving customers in the United States, Canada, Europe, the Middle East, Africa, and internationally. Their commitment to innovation and quality has positioned them as a trusted partner for cell and gene therapy developers and manufacturers worldwide.

What Products and Services Does BLFS Offer?

• Develops and manufactures biopreservation media for cell and gene therapies.
• Provides automated thawing equipment for vials and cryobags.
• Offers cloud-connected passive storage and transport containers for biologics.
• Supplies liquid nitrogen laboratory freezers and cryogenic equipment.
• Provides biological and pharmaceutical storage services.
• Supports basic and applied research in biologic-based therapies.
• Serves the commercial manufacturing of cell and gene therapies.

How Does BLFS Make Money?

• Sells proprietary biopreservation media (HypoThermosol FRS and CryoStor).
• Generates revenue from the sale of ThawSTAR automated thawing products.
• Offers evo shipping containers for temperature-sensitive biologics and pharmaceuticals.
• Provides cryogenic equipment and accessories, including liquid nitrogen freezers.

What Industry Does BLFS Operate In?

BioLife Solutions operates within the rapidly expanding cell and gene therapy market, which is projected to experience significant growth in the coming years. The increasing prevalence of chronic diseases and the growing demand for personalized medicine are driving the development and adoption of cell and gene therapies. BioLife Solutions plays a crucial role in this market by providing essential biopreservation and thawing solutions that ensure the viability and efficacy of these therapies. The competitive landscape includes companies offering alternative preservation methods and cryogenic storage solutions. BioLife Solutions differentiates itself through its proprietary media formulations, automated thawing technology, and comprehensive service offerings.

Who Are BLFS's Key Customers?

• Cell and gene therapy developers.
• Biopharmaceutical manufacturers.
• Research institutions.
• Hospitals and clinical laboratories.

BioLife Solutions, Inc. (BLFS) Valuation Context

Valued at $1.36B, BLFS is classified as a small-cap stock. Relative to its peer group, BLFS's quantitative score of 36/100 is below the peer average of 62/100.

BLFS Revenue & Earnings Trend

In Q1 2026, BLFS generated $27.5M in top-line revenue, marking a sequential increase of 46.4%. The company recorded net income of $1.2M, with diluted EPS of $0.02. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BLFS averaged $-0.05 in diluted EPS.

Company Profile

BioLife Solutions, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Bothell, US. The company is led by CEO Roderick de Greef. BLFS has traded publicly since 1989.

ROE -3%Key Financial Metrics

Return on equity for BioLife Solutions, Inc. stands at -2.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.30 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

BioLife Solutions, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 28.05 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project BioLife Solutions, Inc. revenue of about $113.9M for fiscal 2026, with EPS near $0.15. The estimate reflects 7 contributing analysts.

BLFS Financials

BLFS Latest News

BLFS Analyst Consensus

BLFS MoonshotScore

Latest BioLife Solutions, Inc. Analysis

What Investors Ask About BioLife Solutions, Inc. (BLFS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources